Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 30 years of experience in the Korean/Asian equity research. Major sectors coverage include the following:
- Technology 
- Consumer 
- Special Situations/Deep Value Plays
- Tender Offers/M&As
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

Review of Our IPO Research in 2020 & Change in Our IPO Research Process for 2021

Smartkarma North Asia Weekly: MSCI Deletions, Japan Post Insurance, Yidu Tech, & Korean IPOs in 2021

SK Chemicals: Spinning Out Vaccine Business

Equity Capital Markets

<p>On November 27th, SK Bioscience announced that it plans to complete an IPO as early as in 1H 2021. SK Chemial owns a 98% stake in SK Bioscience. SK Bioscience plans to submit the IPO application to the Korea Exchange on December 1st. The Korea Exchange will then announce its decision as to whether to approve this IPO application within 45 days. If this application is approved, SK Bioscience is likely to complete its IPO in 1H 2021 on KOSPI. NH Investment &amp; Securities has been selected as the lead underwriter of this IPO. Korea Investment &amp; Securities and Mirae Asset Dawoo Securities are the joint book runners.</p><div class="content-highlight"><p>The local media have mentioned that the value of SK Bioscience could be at least 3 trillion won ($2.7 billion). Given the excellent success of SK Biopharm combined with the backing by Bill Gates, SK Bioscience IPO is likely to attract many investors. It is likely that SK Bioscience will be one of the biggest health-care related IPOs in Korea next year.</p></div>

On November 27th, SK Bioscience announced that it plans to complete an IPO as early as in 1H 2021. SK Chemial owns a 98% stake in SK Bioscience. SK Bioscience plans to submit the IPO application to the Korea Exchange on December 1st. The Korea Exchange will then announce its decision as to whether to approve this IPO application within 45 days. If this application is approved, SK Bioscience is likely to complete its IPO in 1H 2021 on KOSPI. NH Investment &amp; Securities has been selected as the lead underwriter of this IPO. Korea Investment &amp; Securities and Mirae Asset Dawoo Securities are the joint book runners.The local media have mentioned that the value of SK Bioscience could be at least 3 trillion won ($2.7 billion). Given the excellent success of SK Biopharm combined with the backing by Bill Gates, SK Bioscience IPO is likely to attract many investors. It is likely that SK Bioscience will be one of the biggest health-care related IPOs in Korea next year.

Initial Thoughts on the SK Bioscience IPO - Backed by Bill Gates